Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Philips subsidiary to pay over $24 million for alleged false claims for medical equipment

Published 01/09/2022, 20:08
Updated 01/09/2022, 21:50
© Reuters. FILE PHOTO: Dutch technology company Philips logo is seen at company headquarters in Amsterdam, Netherlands, January 29, 2019. REUTERS/Eva Plevier

By Kanishka Singh

WASHINGTON (Reuters) -A subsidiary of Dutch medical device maker Philips has agreed to pay over $24 million to resolve alleged false claims over respiratory-related medical equipment, the U.S. Justice Department said on Thursday.

The subsidiary, Philips RS North America LLC, formerly known as Respironics Inc, resolved allegations that it misled federal healthcare programs by paying kickbacks to durable medical equipment suppliers, the Justice Department said in a statement.

Respironics allegedly gave the suppliers physician prescribing data free of charge that could assist their marketing efforts to physicians, the Justice Department said.

"Paying illegal remuneration to induce patient referrals undermines the integrity of our nation’s healthcare system," said Principal Deputy Assistant Attorney General Brian Boynton, head of the Justice Department's civil division.

Respironics also entered into a five-year agreement with the U.S. Department of Health and Human Services, Office of the Inspector General to implement a compliance program that includes review of arrangements with referral sources and monitoring of Respironics' sales force, the Justice Department said.

A Philips spokesperson said its subsidiary agreed to settle the claim to avoid the required expense of litigating the allegations.

"In agreeing to a settlement, Philips Respironics is not acknowledging any alleged facts, liability, or wrongdoing in the claim," the company spokesperson said in an emailed statement.

"This agreement should have no impact on our customers or the patients they serve," the company added

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.